Details
| Stereochemistry | RACEMIC |
| Molecular Formula | 2C3H5O3.Ca.H2O |
| Molecular Weight | 236.233 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.[Ca++].CC(O)C([O-])=O.CC(O)C([O-])=O
InChI
InChIKey=MDAVASCOAJMZHZ-UHFFFAOYSA-L
InChI=1S/2C3H6O3.Ca.H2O/c2*1-2(4)3(5)6;;/h2*2,4H,1H3,(H,5,6);;1H2/q;;+2;/p-2
| Molecular Formula | C3H5O3 |
| Molecular Weight | 89.07 |
| Charge | -1 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
| Molecular Formula | Ca |
| Molecular Weight | 40.078 |
| Charge | 2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.htmlhttp://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttp://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479Curator's Comment: description was created based on several sources, including
https://www.alfa.com/en/catalog/043674/
Sources: https://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.htmlhttp://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttp://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479
Curator's Comment: description was created based on several sources, including
https://www.alfa.com/en/catalog/043674/
Calcium lactate is the salt that consists of two lactate anions for each calcium cation (Ca2+); this salt is used as a calcium supplement to treat hypocalcemia. However, as a source of free calcium, this salt is less convenient than calcium citrate. Calcium lactate inhalation powder also called as PUR118 participated in phase I clinical trials to determine whether this formulation was safe and tolerable in a population of subjects with Cystic Fibrosis (CF). PUR118 also was used in another clinical trials to evaluate its effect on ozone-induced airway Inflammation in healthy normal volunteers in case of Chronic Obstructive Pulmonary Disease (COPD). The obtained results revealed that PUR118 reduced the severity of acute exacerbations in COPD and CF and had the beneficial impacts on mortality, morbidity, and quality of life in affected individuals. However, both studies were discontinued.
Originator
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseHypocalcemia, chronic (treatment) — Oral calcium supplements provide a source of calcium ion for treating calcium depletion occurring in conditions such as chronic hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, rickets, chronic renal failure, and hypocalcemia secondary to the administration of anticonvulsant medications. When chronic hypocalcemia is due to vitamin D deficiency, oral calcium salts may be administered concomitantly with vitamin D analogs. However, calcium phosphate should not be used in patients with hypoparathyroidism or renal failure, since phosphate levels may be too high and giving more phosphate would exacerbate the condition. Calcium supplements should not be used in hyperparathyroidism, unless the need for a calcium supplement is high and the patient is carefully monitored. For treatment of hypocalcemia, supplementation is preferred |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effects of terbutaline on force and intracellular calcium in slow-twitch skeletal muscle fibres of the rat. | 1999 Apr |
|
| A novel ubiquitously expressed alpha-latrotoxin receptor is a member of the CIRL family of G-protein-coupled receptors. | 1999 Feb 26 |
|
| [Early stage of cardiomyopathy: mechanisms of damage and compensation]. | 1999 Jul |
|
| Characterization of the human cysteinyl leukotriene CysLT1 receptor. | 1999 Jun 24 |
|
| Regulation of Na/K-ATPase beta1-subunit gene expression by ouabain and other hypertrophic stimuli in neonatal rat cardiac myocytes. | 2000 Dec |
|
| Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. | 2000 Dec |
|
| Effect of ADP and ionic strength on the kinetic and motile properties of recombinant mouse myosin V. | 2000 Feb 11 |
|
| Neuropeptide Y (NPY) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y5 receptors. | 2000 Feb 15 |
|
| Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. | 2000 Jan 7 |
|
| Calmodulin kinases II and IV and calcineurin are involved in leukemia inhibitory factor-induced cardiac hypertrophy in rats. | 2000 Nov 10 |
|
| ATP induces dephosphorylation of myosin light chain in endothelial cells. | 2000 Sep |
|
| Molecular and functional characterization of a family of rat brain T-type calcium channels. | 2001 Feb 9 |
|
| Extracellular calcium-sensing receptor is expressed in rat hepatocytes. coupling to intracellular calcium mobilization and stimulation of bile flow. | 2001 Feb 9 |
|
| Mechanisms of regulation of agonist efficacy at the 5-HT(1A) receptor by phospholipid-derived signaling components. | 2001 Jun |
|
| Cloning and characterization of a novel human histamine receptor. | 2001 Mar |
|
| Tight control of exogenous SERCA expression is required to obtain acceleration of calcium transients with minimal cytotoxic effects in cardiac myocytes. | 2001 Mar 2 |
|
| Oxidative impairment in scrapie-infected mice is associated with brain metals perturbations and altered antioxidant activities. | 2001 Nov |
|
| Hypoxia-induced regulation of MAPK phosphatase-1 as identified by subtractive suppression hybridization and cDNA microarray analysis. | 2001 Nov 30 |
|
| Microarray analysis of differential gene expression in lead-exposed astrocytes. | 2001 Oct 1 |
|
| Human kidney diamine oxidase: heterologous expression, purification, and characterization. | 2002 Jun |
|
| Inhibition of peroxisome proliferator-activated receptor (PPAR)-mediated keratinocyte differentiation by lipoxygenase inhibitors. | 2002 Sep 15 |
|
| [Prevention of osteoporosis by foods and dietary supplements. Bioavailability of milk micellar calcium phosphate]. | 2006 Oct |
|
| Henri Moissan: winner of the Nobel Prize for Chemistry 1906. | 2006 Oct 20 |
|
| Dietary calcium source influences body composition, glucose metabolism and hormone levels in a mouse model of postmenopausal obesity. | 2009 Jul-Aug |
|
| Long-term remineralizing effect of casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) on early caries lesions in vivo: a systematic review. | 2014 Jul |
|
| Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model--a clinical trial. | 2015 Aug 12 |
|
| Dietary interventions for mineral and bone disorder in people with chronic kidney disease. | 2015 Sep 16 |
Sample Use Guides
Proper administration of calcium carbonate or phosphate: Taking tablets 1 to 11/2 hours after meals, unless otherwise directed by physician. Recommended doses for adolescents and adults is 800-1200 mg/day; for pregnat orbreast-feeding females 1200 mg/day.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 20:39:56 GMT 2025
by
admin
on
Mon Mar 31 20:39:56 GMT 2025
|
| Record UNII |
679364496I
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000134149
Created by
admin on Mon Mar 31 20:39:56 GMT 2025 , Edited by admin on Mon Mar 31 20:39:56 GMT 2025
|
PRIMARY | |||
|
679364496I
Created by
admin on Mon Mar 31 20:39:56 GMT 2025 , Edited by admin on Mon Mar 31 20:39:56 GMT 2025
|
PRIMARY | |||
|
SUB59793
Created by
admin on Mon Mar 31 20:39:56 GMT 2025 , Edited by admin on Mon Mar 31 20:39:56 GMT 2025
|
PRIMARY | |||
|
5282393
Created by
admin on Mon Mar 31 20:39:56 GMT 2025 , Edited by admin on Mon Mar 31 20:39:56 GMT 2025
|
PRIMARY | |||
|
69843-88-5
Created by
admin on Mon Mar 31 20:39:56 GMT 2025 , Edited by admin on Mon Mar 31 20:39:56 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ANHYDROUS->SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
